Dr. Fahmeedah Shaukath Kamal, MD

Dr. Kamal practices at Redwood City Medical Center in Redwood City, California, part of Kaiser Permanente.

Dr. Kamal's NPI, 1154579969, was assigned on September 4, 2008. Dr. Kamal graduated from UMKC School of Medicine in 2007. Dr. Kamal holds California license A134411.

Dr. Kamal's primary practice is Redwood City Medical Center, at 1100 Veterans Boulevard, Redwood City, CA 94063 in San Mateo County. The practice phone is (650) 299-2000.

Dr. Kamal's primary practice is Redwood City Medical Center in Redwood City, California, part of Kaiser Permanente. Dr. Kamal is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Kamal to 1 more hospital, 2 dialysis centers and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamal practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Kamal's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Kamal is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Kamal's licenses on file in 4 states: California, North Carolina, Rhode Island and Missouri.

Dmand AI lists acute kidney failure, chronic hypertension, chronic kidney disease, fluid and electrolyte imbalances, gastrointestinal inflammation, hypercalcemia, kidney disease and kidney stone disease among the conditions Dr. Kamal treats.

CMS data shows 724 Medicare services from Dr. Kamal across 11 procedure codes in 2024, for 294 Medicare patients. Medicare paid $84,526 for them.

CMS counts 294 Medicare patients who saw Dr. Kamal in 2024. The largest group is 75 to 84, with 101 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 38% are also on Medicaid. Their average risk score is 4.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kamal's median patient age at 57, with 49% women.

In 2024, Dr. Kamal wrote 519 Medicare Part D claims for 103 patients. 81% of them were for generic drugs. CMS names the drug for 393 of them, across 15 drugs with 11 or more claims each, at $71,995 in total drug cost. In 2023, CMS named 550 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Kamal for performance year 2024, reported as part of a group. Dr. Kamal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kamal as offering telehealth.

Dmand AI links 3 papers to Dr. Kamal, published from 2019 to 2025. The most frequent topics are Glomerulonephritis, IGA and Immunoglobulin A. Dr. Kamal's most frequent co-authors are Richard Alan Lafayette, MD, Glenn Matthew Chertow, MD and Jackson Peter Kim, MD.

CMS Open Payments shows 29 general payments to Dr. Kamal from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 39% of the total. Travere Therapeutics, Inc. paid the most, $9,197.

Dr. Kamal graduated from UMKC School of Medicine in 2007.

Dr. Kamal is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.